Andere Kunden interessierten sich auch für
![Ein Leitfaden für die Registrierung von Generika in Indien]( "Ein Leitfaden für die Registrierung von Generika in Indien")
Ein Leitfaden für die Registrierung von Generika in Indien71,90 €![KAP de Pharmacist & Physician towards Generic Drug Use]( "KAP de Pharmacist & Physician towards Generic Drug Use")
KAP de Pharmacist & Physician towards Generic Drug Use26,99 €![Formulation development of generic omeprazole enteric coated tablets]( "Formulation development of generic omeprazole enteric coated tablets")
Formulation development of generic omeprazole enteric coated tablets26,99 €![International Regulatory Approaches to Bioequivalence of Generic OIDPs]( "International Regulatory Approaches to Bioequivalence of Generic OIDPs")
International Regulatory Approaches to Bioequivalence of Generic OIDPs32,99 €![Registration Process of Generic Budesonide DPI as per USFDA Guidelines]( "Registration Process of Generic Budesonide DPI as per USFDA Guidelines")
Registration Process of Generic Budesonide DPI as per USFDA Guidelines40,99 €![A Guidebook to Generic Drug registration in India]( "A Guidebook to Generic Drug registration in India")
A Guidebook to Generic Drug registration in India46,99 €![KAP of Pharmacist & Physician towards Generic Drug Use]( "KAP of Pharmacist & Physician towards Generic Drug Use")
KAP of Pharmacist & Physician towards Generic Drug Use26,99 €
Generic drugs are now familiar objects in clinics, drugstores, and households around the world. We like to think of these tablets, capsules, patches, and ointments as interchangeable with their brand-name counterparts: why pay more for the same? And yet they are not quite the same. They differ in price, in place of origin, in color, shape, and size, in the dyes, binders, fillers, and coatings used, and in a host of other ways. Claims of generic equivalence, as physician-historian Jeremy Greene reveals in this gripping narrative, are never based on being identical to the original drug in all respects, but in being the same in all ways that matter.
How do we know what parts of a pill really matter? Decisions about which differences are significant and which are trivial in the world of therapeutics are not resolved by simple chemical or biological assays alone. As Greene reveals in this fascinating account, questions of therapeutic similarity and difference are also always questions of pharmacology and physiology, of economics and politics, of morality and belief.
Generic is the first book to chronicle the social, political, and cultural history of generic drugs in America. It narrates the evolution of the generic drug industry from a set of mid-twentieth-century "schlock houses" and "counterfeiters" into an agile and surprisingly powerful set of multinational corporations in the early twenty-first century.
The substitution of bioequivalent generic drugs for more expensive brand-name products is a rare success story in a field of failed attempts to deliver equivalent value in health care for a lower price. Greenes history sheds light on the controversies shadowing the success of generics: problems with the generalizability of medical knowledge, the fragile role of science in public policy, and the increasing role of industry, marketing, and consumer logics in late-twentieth-century and early twenty-first century health care.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
How do we know what parts of a pill really matter? Decisions about which differences are significant and which are trivial in the world of therapeutics are not resolved by simple chemical or biological assays alone. As Greene reveals in this fascinating account, questions of therapeutic similarity and difference are also always questions of pharmacology and physiology, of economics and politics, of morality and belief.
Generic is the first book to chronicle the social, political, and cultural history of generic drugs in America. It narrates the evolution of the generic drug industry from a set of mid-twentieth-century "schlock houses" and "counterfeiters" into an agile and surprisingly powerful set of multinational corporations in the early twenty-first century.
The substitution of bioequivalent generic drugs for more expensive brand-name products is a rare success story in a field of failed attempts to deliver equivalent value in health care for a lower price. Greenes history sheds light on the controversies shadowing the success of generics: problems with the generalizability of medical knowledge, the fragile role of science in public policy, and the increasing role of industry, marketing, and consumer logics in late-twentieth-century and early twenty-first century health care.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.